Related Experiment Video
Updated: Apr 10, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Economic evaluation of combination vaccines: Enabling a more comprehensive assessment of their benefits and
Frédéric Debellut1, Dagna Constenla2, Mercy Mvundura3
1Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland.
Insights
Developing new combination vaccines for children requires a better understanding of their value. This study created a prioritized checklist of value drivers and metrics to guide economic evaluations and inform decision-making for vaccine adoption.
Area of Science:
- Public Health
- Health Economics
- Vaccinology
Background:
- Combination vaccines are crucial for pediatric immunization but their development has lagged.
- Existing economic evaluations do not fully capture the benefits and risks of combination vaccines.
Purpose of the Study:
- To identify and prioritize potential new combination vaccines.
- To enhance the value assessment of combination vaccines for better decision-making.
Main Methods:
- Literature review of economic evaluations of combination vaccines.
- Identification and categorization of value drivers and metrics.
- Consultative process with immunization stakeholders and health economics experts.
- Development of a prioritized checklist for assessing combination vaccines.
Main Results:
- Identified gaps in current value assessment of combination vaccines.
- Created a categorized list of value drivers and metrics.
- Developed a prioritized checklist endorsed by the World Health Organization's advisory committee.
Conclusions:
- The developed checklist serves as a tool for analysts to comprehensively assess combination vaccines.
- This tool aims to inform investment decisions and adoption by decision-makers.
- Enhancing value assessment is crucial for prioritizing future combination vaccine development.
Abstract:
Even though two widely used combination vaccines (measles-rubella- and diphtheria- tetanus-pertussis-containing vaccines) are universally acknowledged as the cornerstones of pediatric immunization programs, the development of new combination vaccines for children has not been a priority for manufacturers, policy bodies, or decision-makers. At the same time, economic evaluations have not assessed the full array of benefits and risks associated with combination vaccines. As part of an effort to identify and prioritize potential new combination vaccines, we aimed to enhance efforts to establish their value, a crucial step toward a more thorough, quantifiable, and realistic assessment of these vaccines. We reviewed the literature on economic evaluations of combination vaccines to more precisely identify and define current gaps in value assessment. We identified a set of (often unvalued) benefits and risks and created a list of value drivers and metrics for potential inclusion in future evaluations. Value drivers were then categorized based on how they resonate with decision-makers' priorities and their contribution to product value. Metrics were categorized based on their quantifiability and their fit within existing economic evaluation frameworks. We developed a prioritized checklist of value drivers and metrics to assess combination vaccines through a consultative process involving numerous immunization stakeholders (e.g., immunization specialists, regional immunization advisors, policy bodies). The checklist was further refined through a convening of health economics experts and ultimately endorsed by the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee. This checklist of prioritized value drivers and metrics is meant to serve as a tool for analysts to value combination vaccines and help ensure these vaccines are more comprehensively assessed by decision-makers to inform investment decisions or adoption.
More Related Videos
Related Concept Videos
Vaccinations
Vaccines
Vaccine Production
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence of Drugs: Drugs with Multiple Indications

